» Articles » PMID: 38667286

Human-Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Showed Neuronal Differentiation, Neurite Extension, and Formation of Synaptic Structures in Rodent Ischemic Stroke Brains

Abstract

Ischemic stroke is a major cerebrovascular disease with high morbidity and mortality rates; however, effective treatments for ischemic stroke-related neurological dysfunction have yet to be developed. In this study, we generated neural progenitor cells from human leukocyte antigen major loci gene-homozygous-induced pluripotent stem cells (hiPSC-NPCs) and evaluated their therapeutic effects against ischemic stroke. hiPSC-NPCs were intracerebrally transplanted into rat ischemic brains produced by transient middle cerebral artery occlusion at either the subacute or acute stage, and their in vivo survival, differentiation, and efficacy for functional improvement in neurological dysfunction were evaluated. hiPSC-NPCs were histologically identified in host brain tissues and showed neuronal differentiation into vGLUT-positive glutamatergic neurons, extended neurites into both the ipsilateral infarct and contralateral healthy hemispheres, and synaptic structures formed 12 weeks after both acute and subacute stage transplantation. They also improved neurological function when transplanted at the subacute stage with γ-secretase inhibitor pretreatment. However, their effects were modest and not significant and showed a possible risk of cells remaining in their undifferentiated and immature status in acute-stage transplantation. These results suggest that hiPSC-NPCs show cell replacement effects in ischemic stroke-damaged neural tissues, but their efficacy is insufficient for neurological functional improvement after acute or subacute transplantation. Further optimization of cell preparation methods and the timing of transplantation is required to balance the efficacy and safety of hiPSC-NPC transplantation.

Citing Articles

Deep brain stimulation combined with morroniside promotes neural plasticity and motor functional recovery after ischemic stroke.

Chen Y, Xu Z, Ma Y, Liu T, Tian X, Zhu Z Front Pharmacol. 2024; 15:1457309.

PMID: 39697542 PMC: 11652210. DOI: 10.3389/fphar.2024.1457309.

References
1.
Jensen M, Yan H, Krishnaney-Davison R, Al Sawaf A, Zhang S . Survival and differentiation of transplanted neural stem cells derived from human induced pluripotent stem cells in a rat stroke model. J Stroke Cerebrovasc Dis. 2011; 22(4):304-8. PMC: 3295911. DOI: 10.1016/j.jstrokecerebrovasdis.2011.09.008. View

2.
Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A . An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2012; 31(3):458-66. DOI: 10.1002/stem.1293. View

3.
Bederson J, Pitts L, Tsuji M, Nishimura M, Davis R, Bartkowski H . Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986; 17(3):472-6. DOI: 10.1161/01.str.17.3.472. View

4.
Nishino H, Aihara N, Czurko A, Hashitani T, Isobe Y, Ichikawa O . Reconstruction of GABAergic transmission and behavior by striatal cell grafts in rats with ischemic infarcts in the middle cerebral artery. J Neural Transplant Plast. 1993; 4(2):147-55. PMC: 2565254. DOI: 10.1155/NP.1993.147. View

5.
Polentes J, Jendelova P, Cailleret M, Braun H, Romanyuk N, Tropel P . Human induced pluripotent stem cells improve stroke outcome and reduce secondary degeneration in the recipient brain. Cell Transplant. 2012; 21(12):2587-602. DOI: 10.3727/096368912X653228. View